Benitec Biopharma Inc (BNTC) - Financial and Strategic SWOT Analysis Review

October 2021 | 47 pages | ID: B294B7B6A8AEN
GlobalData

Abstracts

Benitec Biopharma Inc (BNTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Benitec Biopharma Inc (Benitec) is a clinical stage biotechnology company. It develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary gene silencing DNA directed RNA interference (ddRNAi) technology. The company’s pipeline products include BB-301 for oculopharyngeal muscular dystrophy (OPMD) and BB-103 for treatment of hepatitis B. It also licenses ddRNAi to various biopharmaceutical companies for the development of drugs. Benitec is headquartered in Hayward, California, the US.

Benitec Biopharma Inc Key Recent Developments

Sep 20,2021: Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Sep 23,2020: Benitec Biopharma provides operational update and releases its 2020 fiscal year-end financial results
Apr 14,2020: Benitec Biopharma appoints Edward Smith to the board of directors
Mar 30,2020: Benitec announces Supreme Court of Queensland approval for Redomicile
Jan 31,2020: Benitec Biopharma announces appendix 4C: quarterly cash flow report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Benitec Biopharma Inc - Key Facts
Benitec Biopharma Inc - Key Employees
Benitec Biopharma Inc - Key Employee Biographies
Benitec Biopharma Inc - Major Products and Services
Benitec Biopharma Inc - History
Benitec Biopharma Inc - Company Statement
Benitec Biopharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Benitec Biopharma Inc - Business Description
Benitec Biopharma Inc - Corporate Strategy
Benitec Biopharma Inc - SWOT Analysis
SWOT Analysis - Overview
Benitec Biopharma Inc - Strengths
Benitec Biopharma Inc - Weaknesses
Benitec Biopharma Inc - Opportunities
Benitec Biopharma Inc - Threats
Benitec Biopharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Benitec Biopharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 20, 2021: Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Sep 23, 2020: Benitec Biopharma provides operational update and releases its 2020 fiscal year-end financial results
Apr 14, 2020: Benitec Biopharma appoints Edward Smith to the board of directors
Mar 30, 2020: Benitec announces Supreme Court of Queensland approval for Redomicile
Jan 31, 2020: Benitec Biopharma announces appendix 4C: quarterly cash flow report

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Benitec Biopharma Inc, Key Facts
Benitec Biopharma Inc, Key Employees
Benitec Biopharma Inc, Key Employee Biographies
Benitec Biopharma Inc, Major Products and Services
Benitec Biopharma Inc, History
Benitec Biopharma Inc, Subsidiaries
Benitec Biopharma Inc, Key Competitors
Benitec Biopharma Inc, Ratios based on current share price
Benitec Biopharma Inc, Annual Ratios
Benitec Biopharma Inc, Annual Ratios (Cont...1)
Benitec Biopharma Inc, Interim Ratios
Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Benitec Biopharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Benitec Biopharma Inc, Performance Chart (2017 - 2021)
Benitec Biopharma Inc, Ratio Charts
Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Benitec Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021